684. Risk Stacking for Pneumococcal Disease in Costa Rica
Session: Poster Abstract Session: Public Health: Epidemiology and Outbreaks
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • IDW684 Risk Stacking for Pneumococcal Disease in Costa Rica.pdf (401.6 kB)
  • RISK STACKING FOR PNEUMOCOCCAL DISEASE IN COSTA RICA

    Background: The value of non-traditional high-risk factor stacking is not known in the Costa Rican population. We aim to describe risk factor stacking for pneumococcal disease (PD) in patients seeking care at Social Security Hospitals in Costa Rica

    Methods: Descriptive study of adult patients with microbiological culture-positive Streptococcus pneumoniae disease seeking care at two tertiary hospitals in Costa Rica between years 2014-2016. Information on underlying comorbidities (non-traditional) and other risk factors for PD was analyzed and stalked for each age group (G1: <50, G2: 50-64, and G3: ≥65 y/o).

    Results: We included 181 culture-positive patients. We found that patients in G1 predominantly stacked ≥2 risk factors (63%), the proportion of patients with ≥2 risk factor was similar to high-risk patients in G2 (33% vs 38%). In G3, 18% didn’t stacked any other risk factor and 46% was on high-risk. Most frequent risk factors in G1/G2 were smoking and alcoholism, and in G3 chronic pulmonary and heart diseases.

    Conclusion: We conclude that risk factor stacking is more relevant than high-risk conditions and PD also occurs in persons < 50 y/o. We recommend that risk factor stacking should be considered in prevention strategies for PD.

    Figure%201%20.jpg

    Figure%202.jpg

     

    Jorge Chaverri-Murillo, MD1, Manuel Ramírez-Cardoce, MD1 and José Castro-Cordero, MD2, (1)Infectious Diseases, Caja Costarricense del Seguro Social, San José, Costa Rica, (2)Infection Control, Caja Costarricense del Seguro Social, San José, Costa Rica

    Disclosures:

    J. Chaverri-Murillo, None

    M. Ramírez-Cardoce, None

    J. Castro-Cordero, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.